New oral drug can stop tumours from growing
The oral NLRP3 inhibitor used in the study (Dapansutrile) has already shown to be effective in clinical trials to treat gout and heart disease, and it is currently being tested in Covid-19 as well.
The oral NLRP3 inhibitor used in the study (Dapansutrile) has already shown to be effective in clinical trials to treat gout and heart disease, and it is currently being tested in Covid-19 as well.
Risk of oral clefts is most pronounced in women taking higher doses of topiramate to treat epilepsy.
